

# Immix Biopharma

## \$9m private placement to support operations

Financial update

Healthcare

12 September 2025

Immix Biopharma has released a financing and business update, reinforcing its focus on advancing the development of lead CAR-T candidate NXC-201. The company has announced a private placement from Goose Capital amounting to \$9.1m (gross proceeds). It was noted that this strategic investment was led by Dr Nancy T Chang, one of the founders of Goose Capital. Dr Chang is a highly respected biotech executive, having led the development of Xolair (omalizumab, for severe asthma), Trogarzo (ibalizumab-uiyk, for HIV) and Ebglyss (lebrizumab-lbkz, for dermatitis) through to FDA approval and subsequent commercialisation, collectively generating over \$5bn in sales to date. She is also the former CEO of Tanox, which was acquired by Genentech/Roche in 2007. We therefore view the investment as an encouraging recognition of the potential of NXC-201, in particular for the treatment of amyloid light chain amyloidosis (ALA), the lead indication being targeted. The proceeds should extend Immix's cash runway beyond near-term operational needs.

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/23	0.0	(13.0)	(0.75)	0.00	N/A	N/A
12/24	0.0	(18.6)	(0.66)	0.00	N/A	N/A
12/25e	0.0	(18.8)	(0.62)	0.00	N/A	N/A
12/26e	0.0	(25.7)	(0.82)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.


According to the [announcement](#), Immix has completed a [private placement](#) of c 3.83m common shares at \$2.37 per share, alongside non-transferable warrants for c 2.87m shares exercisable at \$2.00 over 10 years, raising c \$9.1m (before deducting fees and expenses), which will be used for working capital and general corporate purposes. This adds to prior funding support, including the \$8m grant from the California Institute for Regenerative Medicine as well as the recently announced at-the-market facility, which provides ample operational headroom to execute on upcoming clinical milestones. Notably, this includes continued enrolment for the US-based NEXICART-2 Phase Ib/II trial in patients with relapsed/refractory (r/r) ALA, alongside preparations for subsequent registration-enabling steps. Ultimately, this strategic investment represents encouraging recognition of the potential of NXC-201 to provide a solution for unmet medical needs in ALA (as well as other serious diseases), while addressing the capital intensity that is typical with CAR-T therapy clinical development efforts.

To date, NXC-201 has shown [positive readouts](#) in the clinic. The Israel-based NEXICART-1 trial showed favourable efficacy data, as well as highly encouraging safety outcomes, positioning it as potentially the first outpatient CAR-T therapy. Management expects to build on these results with the US-based NEXICART-2 trial, which is an open-label, single-arm, multi-site dose escalation/expansion Phase Ib/II trial, aiming to treat 40 r/r ALA patients, after which management plans to submit a biologics licence application to the FDA. Key upcoming milestones for investor attention include NEXICART-2 enrolment completion and the final top-line clinical data report, guided by management for Q425/Q126 and Q2/Q326, respectively. Beyond ALA, Immix plans to expand the application of NXC-201 to other serious diseases, for which the next update is expected in Q226.

For a more detailed overview of Immix's current activities, we direct readers to our [prior update note](#).

<b>Price</b>	<b>\$2.17</b>
<b>Market cap</b>	<b>\$64m</b>
Pro forma net cash at 30 June 2025 (including proceeds from the ATM facility and private placement)	\$22.0m
Shares in issue (including additional shares issued from the ATM facility; excluding new shares from the private placement)	29.3m
Free float	60.0%
Code	IMMX
Primary exchange	NASDAQ
Secondary exchange	N/A

### Share price performance



### Business description

Immix Biopharma is a clinical-stage biopharma company developing personalised therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis with plans to expand to autoimmune indications. A Phase I/II trial, NEXICART-2, is ongoing in the US, with top-line results expected in mid-CY26. The company is also seeking strategic options for legacy asset IMX-110, targeting solid tumours.

### Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**Immix Biopharma is a research client of Edison Investment Research Limited**

---

## General disclaimer and copyright

This report has been commissioned by Immix Biopharma and prepared and issued by Edison, in consideration of a fee payable by Immix Biopharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

---

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

## United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

## United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

---